Novel insights into metabolic sequelae of obstructive sleep apnoea: A link between hypoxic stress and chronic diabetes complications

Diabetes Research and Clinical Practice

Volumn 104, Issue 2, 2014, Pages 197-205

  Pallayova, Maria ^a   Banerjee, Dev ^d,e   Taheri, Shahrad ^b,c  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Diabetes macrovascular complications; Diabetes microvascular complications; Intermittent hypoxemia; Obstructive sleep apnoea; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; BENFOTIAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLICLAZIDE; HEMOGLOBIN A1C; METFORMIN; PENTOXIFYLLINE; PIOGLITAZONE; THIOCTIC ACID;

APNEA HYPOPNEA INDEX; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DYSGLYCEMIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOXIA; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; OXYGEN DESATURATION; PATHOGENESIS; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; REVIEW; SLEEP DISORDERED BREATHING; CARDIOVASCULAR RISK; CELL DAMAGE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; ENDOTHELIUM CELL; MESANGIUM CELL; OBSERVATIONAL STUDY; PERIPHERAL NERVE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY;

DIABETES MACROVASCULAR COMPLICATIONS; DIABETES MICROVASCULAR COMPLICATIONS; INTERMITTENT HYPOXEMIA; OBSTRUCTIVE SLEEP APNOEA; OXIDATIVE STRESS;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; METABOLIC SYNDROME X; OXIDATIVE STRESS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84899080161     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.01.007     Document Type: Review

References (79)

1. Krolewski A.S., Warram J.H. Epidemiology of late complications of diabetes: a basis for the development and evaluation of preventive program. Joslin's diabetes mellitus 2005, Lippincott, Williams & Wilkins, New York. C.R. Kahn, G.C. Weir, G.L. King, A.M. Jacobson, A.C. Moses, R.J. Smith (Eds.).
2. Guariguata L., Whiting D.R., Hambleton I., Beagle J., Linnenkamp U., Shaw J.E. Global estimates of diabetes prevalence for 2013 and projections for 2035 for the IDF Diabetes Atlas. Diab Res Clin Pract 2013, Available online 01.12.13. 10.1016/j.diabres.2013.11.002.
3. International Diabetes Federation IDF Diabetes Atlas Update 2012 2012, Available from: http://www.idf.org/diabetesatlas/5e/Update2012 [accessed 14.12.12].
4. Wilcox I., McNamara S.G., Collins F.L., Grunstein R.R., Sullivan C.E. "Syndrome Z": the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax 1998, 53:S25-S28.
5. Punjabi N.M., Shahar E., Redline S., Gottlieb D.J., Givelber R., Resnick H.E. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol 2004, 160:521-530.
6. Punjabi N.M., Beamer B.A. Alterations in glucose disposal in sleep disordered breathing. Am J Respir Crit Care Med 2009, 179:235-240.
7. Aronsohn R.S., Whitmore H., Van Cauter E., Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med 2010, 181:507-513.
8. Priou P., Le Vaillant M., Meslier N., Chollet S., Masson P., Humeau M.P., et al. Independent association between obstructive sleep apnea severity and glycated hemoglobin in adults without diabetes. Diabetes Care 2012, 35:1902-1906.
9. Monnier L., Colette C., Owens D.R. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?. J Diabetes Sci Technol 2008, 2:1094-1100.
10. Stratton I.M., Adler A.L., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
11. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995, 18:258-268.
12. Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
13. Monnier L., Colette C. Glycemic variability: should we and can we prevent it?. Diabetes Care 2008, 31:S150-S154.
14. Colette C., Monnier L. Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res 2007, 39:683-686.
15. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
16. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005, 54:1615-1625.
17. Gabbay K.H., Merola L.O., Field R.A. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science 1966, 151:209-210.
18. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., Zhang J., et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995, 96:1395-1403.
19. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 1998, 47:859-866.
20. Du X.L., Edelstein D., Rossetti L., Fantus I.G., Goldberg H., Ziyadeh F., et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 2000, 97:12222-12226.
21. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295:1681-1687.
22. Ceriello A., Esposito K., Piconi L., Ihnat M.A., Thorpe J.E., Testa R., et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 57:1349-1354.
23. Doria A. Genetics of diabetes complications. Curr Diab Rep 2010, 10:467-475.
24. Engerman R.L., Kern T.S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987, 36:808-812.
25. Pop-Busui R., Herman W.H., Feldman E.L., Low P.A., Martin C.L., Cleary P.A., et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010, 10:276-282.
26. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1565-1576.
27. Ceriello A., Ihnat M.A., Thorpe J.E. Clinical review 2: the "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?. J Clin Endocrinol Metab 2009, 94:410-415.
28. McGinley B.M., Schwartz A.R., Schneider H., Kirkness J.P., Smith P.L., Patil S.P. Upper airway neuromuscular compensation during sleep is defective in obstructive sleep apnea. J Appl Physiol 2008, 105:197-205.
29. Peppard P.E., Young T., Palta M., Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000, 342:1378-1384.
30. Shahar E., Whitney C., Redline S., Lee E.T., Newman A.B., Nieto F.J., et al. Sleep disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001, 163:19-25.
31. Levy P., Bonsignore M.R., Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009, 34:243-260.
32. Henley D.E., Russell G.M., Douthwaite J.A., Wood S.A., Buchanan F., Gibson R., et al. Hypothalamic-pituitary-adrenal axis activation in obstructive sleep apnea: the effect of continuous positive airway pressure therapy. J Clin Endocrinol Metab 2009, 94:4234-4242.
33. Ryan S., Taylor C.T., McNicholas W.T. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005, 112:2660-2667.
34. Selmi C., Montano N., Furlan R., Keen C.L., Gershwin M.E. Inflammation and oxidative stress in obstructive sleep apnea syndrome. Exp Biol Med (Maywood) 2007, 232:1409-1413.
35. Yamauchi M., Nakano H., Maekawa J., Okamoto Y., Ohnishi Y., Suzuki T., et al. Oxidative stress in obstructive sleep apnea. Chest 2005, 127:1674-1679.
36. Oltmanns K.M., Gehring H., Rudolf S., Schultes B., Rook S., Schweiger U., et al. Hypoxia causes glucose intolerance in humans. Am J Respir Crit Care Med 2004, 169:1231-1237.
37. Stamatakis K.A., Punjabi N.M. Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest 2010, 137:95-101.
38. Louis M., Punjabi N.M. Effects of acute intermittent hypoxia on glucose metabolism in awake healthy volunteers. J Appl Physiol 2009, 106:1538-1544.
39. Shpirer I., Rapoport M.J., Stav D., Elizur A. Normal and elevated HbA1C levels correlate with severity of hypoxemia in patients with obstructive sleep apnea and decrease following CPAP treatment. Sleep Breath 2012, 16:461-466.
40. Yang D., Liu Z., Yang H., Luo Q. Effects of continuous positive airway pressure on glycemic control and insulin resistance in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath 2013, 17:33-38.
41. Iftikhar I.H., Blankfield R.P. Effect of continuous positive airway pressure on hemoglobin A(1c) in patients with obstructive sleep apnea: a systematic review and meta-analysis. Lung 2012, 190:605-611.
42. Myhill P.C., Davis W.A., Peters K.E., Chubb S.A., Hillman D., Davis T.M. Effect of continuous positive airway pressure therapy on cardiovascular risk factors in patients with type 2 diabetes and obstructive sleep apnea. J Clin Endocrinol Metab 2012, 97:4212-4218.
43. Pallayova M., Donic V., Tomori Z. Beneficial effects of severe sleep apnea therapy on nocturnal glucose control in persons with type 2 diabetes mellitus. Diab Res Clin Pract 2008, 81:e8-e11.
44. Dawson A., Abel S.L., Loving R.T., Dailey G., Shadan F.F., Cronin J.W., et al. CPAP therapy of obstructive sleep apnea in type 2 diabetics improves glycemic control during sleep. J Clin Sleep Med 2008, 4:538-542.
45. West S.D., Nicoll D.J., Wallace T.M., Matthews D.R., Stradling J.R. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007, 62:969-974.
46. Hoyos C.M., Killick R., Yee B.J., Phillips C.L., Grunstein R.R., Liu P.Y. Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnoea: a randomised sham-controlled study. Thorax 2012, 67:1081-1089.
47. Narkiewicz K., Somers V.K. The sympathetic nervous system and obstructive sleep apnea: implications for hypertension. J Hypertens 1997, 15:1613-1619.
48. Thomas P.K. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997, 46:S54-S57.
49. Schober A.-K., Neurath M.F., Harsch I.A. Prevalence of sleep apnoea in diabetic patients. Clin Respir J 2011, 5:165-172.
50. Tahrani A.A., Ali A., Raymond N.T., Begum S., Dubb K., Mughal S., et al. Obstructive sleep apnea and diabetic neuropathy: a novel association in patients with type 2 diabetes. Am J Respir Crit Care Med 2012, 186:434-441.
51. Appenzeller O., Parks R.D., MacGee J. Peripheral neuropathy in chronic disease of the respiratory tract. Am J Med 1968, 44:873-880.
52. Malik R.A., Masson E.A., Sharma A.K., Lye R.H., Ah-See A.K., Compton A.M., et al. Hypoxic neuropathy: relevance to human diabetic neuropathy. Diabetologia 1990, 33:311-318.
53. Mayer P., Dematteis M., Pépin J.L., Wuyam B., Veale D., Vila A., et al. Peripheral neuropathy in sleep apnea. A tissue marker of the severity of nocturnal desaturation. Am J Respir Crit Care Med 1999, 159:213-219.
54. Nicholl D.D., Ahmed S.B., Loewen A.H., Hemmelgarn B.R., Sola D.Y., Beecroft J.M., et al. Declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia. Chest 2012, 141:1422-1430.
55. Buyukaydin B., Akkoyunlu M.E., Kazancioglu R., Karakose F., Ozcelik H.K., Erkoc R., et al. The effect of sleep apnea syndrome on the development of diabetic nephropathy in patients with type 2 diabetes. Diab Res Clin Pract 2012, 98:140-143.
56. Eckardt K.U., Rosenberger C., Jurgensen J.S., Wiesener M.S. Role of hypoxia in the pathogenesis of renal disease. Blood Purif 2003, 21:253-257.
57. Nangaku M. Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Nephron Exp Nephrol 2004, 98:e8-e12.
58. Ahmed S.B., Ronksley P.E., Hemmelgarn B.R., Tsai W.H., Manns B.J., Tonelli M., et al. Nocturnal hypoxia and loss of kidney function. PLoS ONE 2011, 6:e19029.
59. Chou Y.T., Lee P.H., Yang C.T., Lin C.L., Veasey S., Chuang L.P., et al. Obstructive sleep apnea: a stand-alone risk factor for chronic kidney disease. Nephrol Dial Transplant 2011, 26:2244-2250.
60. Kanbay A., Buyukoglan H., Ozdogan N., Kaya E., Oymak F.S., Gulmez I., et al. Obstructive sleep apnea syndrome is related to the progression of chronic kidney disease. Int Urol Nephrol 2012, 44:535-539.
61. Kinebuchi S., Kazama J.J., Satoh M., Sakai K., Nakayama H., Yoshizawa H., et al. Short-term use of continuous positive airway pressure ameliorates glomerular hyperfiltration in patients with obstructive sleep apnoea syndrome. Clin Sci (Lond) 2004, 107:317-322.
62. Sklar A.H., Chaudhry B.A., Harp R. Nocturnal urinary protein excretion rates in patients with sleep apnea. Nephron 1989, 51:35-38.
63. Saito A., Takeda T., Hama H., Oyama Y., Hosaka K., Tanuma A., et al. Role of megalin, a proximal tubular endocytic receptor, in the pathogenesis of diabetic and metabolic syndrome-related nephropathies: protein metabolic overload hypothesis. Nephrology (Carlton) 2005, 10:S26-S31.
64. Shiba T., Maeno T., Saishin Y., Hori Y., Takahashi M. Nocturnal intermittent serious hypoxia and reoxygenation in proliferative diabetic retinopathy cases. Am J Ophthalmol 2010, 149:959-963.
65. West S.D., Groves D.C., Lipinski H.J., Nicoll D.J., Mason R.H., Scanlon P.H., et al. The prevalence of retinopathy in men with Type 2 diabetes and obstructive sleep apnoea. Diabet Med 2010, 27:423-430.
66. Kosseifi S., Bailey B., Price R., Roy T.M., Byrd R.P., Peiris A.N. The association between obstructive sleep apnea syndrome and microvascular complications in well-controlled diabetic patients. Mil Med 2010, 175:913-916.
67. Laaban J.P., Daenen S., Leger D., Pascal S., Bayon V., Slama G., et al. Prevalence and predictive factors of sleep apnoea syndrome in type 2 diabetic patients. Diabetes Metab 2009, 35:372-377.
68. Lee I.G., Chae S.L., Kim J.C. Involvement of circulating endothelial progenitaor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye 2006, 20:546-552.
69. Tepper O.M., Galiano R.D., Capla J.M., Kalka C., Gagne P.J., Jacobowitz G.R., et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002, 106:2781-2786.
70. Rudrappa S., Warren G., Idris I. Obstructive sleep apnoea is associated with the development and progression of diabetic retinopathy, independent of conventional risk factors and novel biomarkers for diabetic retinopathy. Br J Ophthalmol 2012, 96:1535.
71. Mason R.H., Kiire C.A., Groves D.C., Lipinski H.J., Jaycock A., Winter B.C., et al. Visual improvement following continuous positive airway pressure therapy in diabetic subjects with clinically significant macular oedema and obstructive sleep apnoea: proof of principle study. Respiration 2012, 84:275-282.
72. Yaggi H.K., Concato J., Kernan W.N., Lichtman J.H., Brass L.M., Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005, 353:2034-2041.
73. Selim B., Won C., Yaggi H.K. Cardiovascular consequences of sleep apnea. Clin Chest Med 2010, 31:203-220.
74. Valham F., Mooe T., Rabben T., Stenlund H., Wiklund U., Franklin K.A. Increased risk of stroke in patients with coronary artery disease and sleep apnea: a 10-year follow-up. Circulation 2008, 118:955-960.
75. Rahbar S., Natarajan R., Yerneni K., Scott S., Gonzales N., Nadler J.L. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000, 301:65-77.
76. Miyata T., van Ypersele de Strihou C., Ueda Y., Ichimori K., Inagi R., Onogi H., et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002, 13:2478-2487.
77. Corgnali M., Piconi L., Ihnat M., Ceriello A. Evaluation of gliclazide ability to attenuate the hyperglycaemic 'memory' induced by high glucose in isolated human endothelial cells. Diabetes Metab Res Rev 2008, 24:301-309.
78. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003, 9:294-299.
79. Du X., Edelstein D., Brownlee M. Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 2008, 51:1930-1932.